Up­dat­ed: Gilead’s Tecar­tus dropped from list of CAR-Ts with up­dat­ed boxed warn­ings

Ed­i­tor’s Note: Lat­er on Wednes­day the FDA re­leased an up­dat­ed let­ter to Gilead that in­cludes Tecar­tus in the list of CAR-T drugs that could cause sec­ondary can­cers.

Gilead’s Tecar­tus has been re­moved from the FDA’s list of CAR-T ther­a­pies that should have a boxed warn­ing on the risks of sec­ondary can­cer af­ter telling five oth­er mak­ers of the drug class to add the warn­ing last week.

The agency wrote five safe­ty com­mu­ni­ca­tions dat­ed Jan. 19 that in­clud­ed warn­ings say­ing ex­plic­it­ly that T cell ma­lig­nan­cies “have oc­curred” af­ter treat­ment with CAR-T ther­a­pies. The sixth stood out: The let­ter for Tecar­tus was writ­ten as these con­cerns “may oc­cur.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER